Bell Potter Oncosil Medical (OSL) (Speculative) Following a long period of sustained effort, Oncosil Medical is finally on the verge of obtaining a CE Mark in Europe. This should lead to first commercial revenues in 2020. Oncosil has a brachytherapy device for the treatment of inoperable pancreatic cancer as well as for use in down staging of borderline cases such that patients become eligible for surgical cure. Data from the 42 patient trial conducted in Europe and Australia demonstrated an impressive survival benefit compared to patients treated with the standard of care. The overall survival benefit is at least 3 months with 50% of patients still alive and in long term follow up. We expect the company will receive a humanitarian device exemption in the United States in 2020 and this is likely to be followed by a larger clinical program at some point.
OSL Price at posting:
15.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)